These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27751897)

  • 1. Cardiovascular Risks of Exogenous Testosterone Use Among Men: A Systematic Review and Meta-Analysis.
    Alexander GC; Iyer G; Lucas E; Lin D; Singh S
    Am J Med; 2017 Mar; 130(3):293-305. PubMed ID: 27751897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis.
    Wong AYS; Chan EW; Anand S; Worsley AJ; Wong ICK
    Drug Saf; 2017 Aug; 40(8):663-677. PubMed ID: 28397186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials.
    Haddad RM; Kennedy CC; Caples SM; Tracz MJ; Boloña ER; Sideras K; Uraga MV; Erwin PJ; Montori VM
    Mayo Clin Proc; 2007 Jan; 82(1):29-39. PubMed ID: 17285783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews.
    Onasanya O; Iyer G; Lucas E; Lin D; Singh S; Alexander GC
    Lancet Diabetes Endocrinol; 2016 Nov; 4(11):943-956. PubMed ID: 27669646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone therapy and cardiovascular risk: advances and controversies.
    Morgentaler A; Miner MM; Caliber M; Guay AT; Khera M; Traish AM
    Mayo Clin Proc; 2015 Feb; 90(2):224-51. PubMed ID: 25636998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies.
    Corona G; Rastrelli G; Di Pasquale G; Sforza A; Mannucci E; Maggi M
    J Sex Med; 2018 Jun; 15(6):820-838. PubMed ID: 29803351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study.
    Wallis CJ; Lo K; Lee Y; Krakowsky Y; Garbens A; Satkunasivam R; Herschorn S; Kodama RT; Cheung P; Narod SA; Nam RK
    Lancet Diabetes Endocrinol; 2016 Jun; 4(6):498-506. PubMed ID: 27165609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clarithromycin use and the risk of mortality and cardiovascular events: A systematic review and meta-analysis.
    You CH; Lin CK; Chen PH; Park S; Chen YY; Khan N; Papatheodorou SI; Chen ST
    PLoS One; 2019; 14(12):e0226637. PubMed ID: 31881052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testosterone, aging and survival: biomarker or deficiency.
    Shores MM; Matsumoto AM
    Curr Opin Endocrinol Diabetes Obes; 2014 Jun; 21(3):209-16. PubMed ID: 24722173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis.
    Fernández-Balsells MM; Murad MH; Lane M; Lampropulos JF; Albuquerque F; Mullan RJ; Agrwal N; Elamin MB; Gallegos-Orozco JF; Wang AT; Erwin PJ; Bhasin S; Montori VM
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2560-75. PubMed ID: 20525906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone and cardiovascular disease.
    Schooling CM
    Curr Opin Endocrinol Diabetes Obes; 2014 Jun; 21(3):202-8. PubMed ID: 24722171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data.
    Carson CC; Rosano G
    J Sex Med; 2012 Jan; 9(1):54-67. PubMed ID: 21676183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between testosterone replacement therapy and cardiovascular outcomes: A meta-analysis of 30 randomized controlled trials.
    Jaiswal V; Sawhney A; Nebuwa C; Borra V; Deb N; Halder A; Rajak K; Jha M; Wajid Z; Thachil R; Bandyopadhyay D; Mattumpuram J; Lavie CJ
    Prog Cardiovasc Dis; 2024; 85():45-53. PubMed ID: 38589271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone replacement therapy and the risk of stroke in men: A systematic review.
    Loo SY; Chen BY; Yu OHY; Azoulay L; Renoux C
    Maturitas; 2017 Dec; 106():31-37. PubMed ID: 29150164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels.
    Vigen R; O'Donnell CI; Barón AE; Grunwald GK; Maddox TM; Bradley SM; Barqawi A; Woning G; Wierman ME; Plomondon ME; Rumsfeld JS; Ho PM
    JAMA; 2013 Nov; 310(17):1829-36. PubMed ID: 24193080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies.
    Mikačić I; Bosnar D
    Drug Saf; 2016 Jun; 39(6):517-41. PubMed ID: 26951234
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.